Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noxa peptide is a cell-permeable peptide derived from the BH3 domain of the pro-apoptotic protein Noxa (PMAIP1). It functions as a BH3 mimetic that selectively binds to and inhibits the anti-apoptotic protein Mcl-1. By sequestering Mcl-1, the peptide releases pro-apoptotic proteins such as Bim, which then initiate the mitochondrial pathway of apoptosis. Research indicates that Noxa peptide can overcome multicellular resistance in 3D tumor spheroids of lung cancer and mesothelioma, particularly when used to sensitize cells to other chemotherapeutic agents or BH3 mimetics like ABT-737. It is primarily used as a research tool to study apoptotic priming and the Bcl-2 family repertoire in various cancer models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Noxa peptide.